APLS
Apellis Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$41.03
+0.00%Sep 2, 2026, 11:30 UTC
The U.S. Court of Appeals for the First Circuit affirmed the dismissal of a putative securities class action against Apellis Pharmaceuticals and its CEO, holding that the company's statements about clinical trial results were not actionable half-truths.
Source:Jun 26, 2026, 13:56 UTC
Biogen completed its $5.6 billion acquisition of Apellis and is now integrating the biotech by terminating most of Apellis' research programs and eliminating a small number of research roles.
Source: